Contribution Of Systemic Inflammatory Response To Brain Injury In Growth Restricted Newborns
Funder
National Health and Medical Research Council
Funding Amount
$363,388.00
Summary
Growth restriction during pregnancy can damage the baby’s brain and result in poor outcomes such as learning and attention difficulties and cerebral palsy. Currently there is no treatment available to prevent brain injury in these babies. This study will explore the role of inflammation and brain injury in the growth restricted baby. We will also examine whether a readily available and safe anti-inflammatory treatment can reduce or prevent brain injury following growth restriction.
The Stunting Risk Assessment Tool: Identifying Infants At High Risk Of Impaired Growth And Development In Resource Poor Settings.
Funder
National Health and Medical Research Council
Funding Amount
$344,644.00
Summary
Stunting is a neglected global health crisis. After the age of 2, irreversible health, developmental and economic consequences occur that are perpetuated across generations. Early risk prediction is key to more effective interventions. By determining the contribution of risk factors in pregnancy and early infancy, I propose to develop a tool that can be used by health workers to identify infants at high risk of stunting in early life, so that early preventive measures can be introduced.
Transcriptional Regulation Of The Tumour Suppressor Gene, Retinoic Acid Receptor Beta
Funder
National Health and Medical Research Council
Funding Amount
$336,540.00
Summary
Cancer is still the second commonest cause of death in children. Neuroblastoma is the commonest solid tumour under the age of five years. Neuroblastoma responds poorly to conventional chemotherapy, unlike many other childhood cancers, and thus represents a major unsolved child health problem. A major advance in the field was a recent trial in th US demonstrating that treatment with oral vitamin A improved survival rates in children with advanced neuroblastoma. In previous studies we have identif ....Cancer is still the second commonest cause of death in children. Neuroblastoma is the commonest solid tumour under the age of five years. Neuroblastoma responds poorly to conventional chemotherapy, unlike many other childhood cancers, and thus represents a major unsolved child health problem. A major advance in the field was a recent trial in th US demonstrating that treatment with oral vitamin A improved survival rates in children with advanced neuroblastoma. In previous studies we have identified that a particular gene retinoic acid receptor beta, known to be involved in the vitamin A anticancer effect may be deficient in some neuroblastoma tumours, and is vital to the anticancer effect of vitamin A in neuroblastoma cells. In this application we hope to define those cellular factors which are necessary for turning on the expression of this gene.Read moreRead less
Trabecular Architecture During Growth - Does It Determine Metaphyseal Peak Bone Strength In Adulthood?
Funder
National Health and Medical Research Council
Funding Amount
$165,339.00
Summary
Skeletal fragility is common is elderly people but has its origin in childhood. Strong bone established during growth will provide more protection against occurrence of fragility fracture in old age. Identifying individuals during childhood who are at high risk of skeletal fragility, and early intervention is a strategic approach managing the burden of skeletal fragility on the ageing population.
Reducing Morbidities In Preterm Growth Restricted Neonates.
Funder
National Health and Medical Research Council
Funding Amount
$687,214.00
Summary
Intrauterine growth restriction (IUGR) is a serious complication of pregnancy and occurs when fetal growth is abnormal, resulting in a fetus that is smaller than it should be for its given gestational age. IUGR babies are at much greater risk of many short and long-term adverse outcomes. This study investigates the role that adverse cardiovascular development plays in the progression of lung, heart and brain disease in preterm IUGR newborns.
Necrotising enterocolitis (NEC) is a devastating bowel condition afflicting almost 1 in 10 of very preterm babies. About a third of babies with NEC do not survive. Currently, there is no cure. We propose the use of stem-like cells from the human placenta as a targeted therapy for NEC, working by minimising gut damage and accelerating gut repair.